RNA transfection

Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Retrieved on: 
Monday, October 17, 2022
RNA transfection, Tick-borne encephalitis, Vaccine, Severe acute respiratory syndrome coronavirus 2, Johnson & Johnson, VLP, Licensure, Janssen Pharmaceuticals, Bavarian Nordic, Monkeypox, OMX, Technology, Goal, Immune system, Rabies, COVID-19, CEO, Adult, Safety, Letter, Vaccination, Forward-looking statement, Government, FDA, Pfizer–BioNTech COVID-19 vaccine, Omicron, ExpreS2ion Biotechnologies

COPENHAGEN, Denmark, October 17, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today the results of a six-month follow-up analysis from a Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.

Key Points: 
  • COPENHAGEN, Denmark, October 17, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today the results of a six-month follow-up analysis from a Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
  • We look forward to generating further data in the ongoing Phase 3 trial that will shortly open sites in Denmark.
  • ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark, using their proprietary capsid virus like particle (cVLP) technology.
  • Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.

PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer

Retrieved on: 
Wednesday, October 19, 2022
Oncology, Professional Services, Health, Insurance, Managed Care, Pharmaceutical, Biotechnology, McGill University, Pharmacology, PIC, RNA transfection, Therapy, Plague, Partner, Complex, Patient, Biotechnology, Drug resistance, Cancer, SAP BusinessObjects Lumira, Goal, EIF4E, Harvard University, Apoptosis, Allosteric regulation, Solution, Pharmaceutical industry

PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, today announced the closing of a $35 million Series A financing led by OrbiMed.

Key Points: 
  • PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, today announced the closing of a $35 million Series A financing led by OrbiMed.
  • PIC Therapeutics is targeting a fundamental mechanism at the convergence of many oncogenic signaling pathways that results in apoptotic cancer cell death while sparing normal cells.
  • PIC Therapeutics targets a master switch of cancer signaling pathways, selectively impacting oncogene protein production by altering the Pre-Initiation Complex (PIC) that drives their mRNA translation.
  • PIC Therapeutics' selective approach modulates cancer cell proteomes, impacting multiple dysregulated oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.

Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Medical Supplies, LinkedIn, Time, RNA transfection, Therapy, Polymer, Vaccine, Technology transfer, GMP, Drug development, Tissue, SM-102, PAA, Arclin, Doctor of Philosophy, PTS, Excipient, Nanoparticle, DNA, LNP, Pharmaceutical industry

Polypeptide Therapeutic Solutions (PTS), a leader in the design, development, and custom manufacturing of polyamino-acid based delivery systems for vaccines and therapeutics, today announced the company has changed its name to Curapath .

Key Points: 
  • Polypeptide Therapeutic Solutions (PTS), a leader in the design, development, and custom manufacturing of polyamino-acid based delivery systems for vaccines and therapeutics, today announced the company has changed its name to Curapath .
  • As part of Curapaths transformation, the company has expanded existing capabilities in development and production of novel functional lipid and polymer excipients and nanoparticle formulations.
  • The expanded capabilities build upon the companys comprehensive portfolio of services which include development, formulation, analytical method development, GMP manufacturing, and fill and finish.
  • The company offers contract development and manufacturing services including preclinical development, analytical characterization, technology transfer, GMP manufacturing, and fill/finish services.

International hub for pharmaceutical tech

Retrieved on: 
Wednesday, October 19, 2022
Genetics, Airea D. Matthews, Medicine, RNA transfection, Bayer, Aspirin, Workforce, Saxony-Anhalt, Vaccine, IMG, Patient, Research, Park, COVID-19, Center of excellence, Leipzig/Halle Airport, EXPO, Patent, WFS, Map, Center, Tablet, Capsule, Saluta Rocks

The "Airea" covers the entire pharmaceutical value chain, from research and development to production, and from marketing to logistics and service.

Key Points: 
  • The "Airea" covers the entire pharmaceutical value chain, from research and development to production, and from marketing to logistics and service.
  • The highly efficient, ultra-modern airport at Leipzig/Halle also has CEIV Pharma certification and can handle temperature- and time-critical pharmaceutical shipments such as vaccines around the clock.
  • The airport offers an international distribution network specifically geared to vaccine and medicine production in Europe, Africa, and the Middle East.
  • You can find more information and articles about the pharmaceutical mecca that is Saxony-Anhalt here .

EXACIS BIOTHERAPEUTICS GRANTS ETERNA THERAPEUTICS AN OPTION TO LICENSE UP TO FOUR ALLOGENEIC IPSC-DERIVED NK AND T CELL THERAPIES

Retrieved on: 
Monday, October 17, 2022
Method, RNA transfection, Therapy, Cell engineering, Virus, Neoplasm, Antibody, Patient, Genetic engineering, Cancer, Immune system, Company, Interim, Eterna, NK, DNA, Engineering, Video game console, Vaccine

The option agreement provides Exacis and Eterna until December 31, 2022 to negotiatethe licenseagreement.

Key Points: 
  • The option agreement provides Exacis and Eterna until December 31, 2022 to negotiatethe licenseagreement.
  • Dr. Dimitri Goundis, Exacis' Chief Business Officer commented, "Exacis is committed to using its powerful platform to produce safe and effective immune cell therapies for cancer.
  • Exacis' allogeneic engineered cell therapies, ExaNK and ExaCAR-NK,are designed to be used alone or in combination with antibodies or NK cell engagers for superior performance.For more information, please visit www.exacis.com .
  • Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications.For more information, please visit www.eternatx.com .

Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

Retrieved on: 
Monday, October 17, 2022
Rubius, Infection, Ribosome, Microbiology, Disease, Therapy, Content discovery platform, Technology, RNA transfection, Growth, Essential amino acid, SANA, NASDAQ, Biology, RNA, Research, Publication, University of Innsbruck, PNAS, Multimedia, Science, Investment, Flagship Pioneering, Protein engineering, University, MRNA, Health, CEO, Ecosystem, Flagship, Cell Metabolism, Springer, David Berry (inventor), Nature Communications, Massachusetts Institute of Technology, Autoimmunity, COVID-19, Language, Leadership, Vaccine, Pharmaceutical industry, Medical device, Fine chemical, Moderna

CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform. 

Key Points: 
  • Under her leadership, Moderna expanded the mechanistic understanding of mRNA design principles underlying current and future mRNA therapeutics, including Moderna's Spikevax mRNA vaccine for COVID-19.
  • "We are excited to have Caroline join us as we boldly establish a first-in-field platform to advance tRNA as a new modality with exceptional and unique therapeutic potential."
  • The company's platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.
  • Alltrna has an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation.

Cancer Patients Treated with Immunotherapy Can Safely Receive mRNA COVID-19 Vaccines, According to JNCCN Study

Retrieved on: 
Monday, October 17, 2022
Vaccine hesitancy, Decision-making, Color, Uncertainty, Caregiver, Memorial Sloan Kettering Cancer Center, RNA transfection, Risk, Medicine, Review, Infection, National Comprehensive Cancer Network, Policy, University of Michigan Rogel Cancer Center, Strathcona County, Vaccine, Education, Patient, NCCN, ICI, Pfizer–BioNTech COVID-19 vaccine, Research, Twitter, Oncology, MSK, Cancer, The Lancet, University, American Cancer Society Cancer Action Network, MD, Journal of the National Comprehensive Cancer Network, Toxicity, Harborside, Health, Immunotherapy, Safety, Vaccination, Bioethics, Public policy, COVID-19, Report, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Oct. 17, 2022 /PRNewswire/ -- New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment. The researchers analyzed the frequency of side effects (also referred to as immune-related adverse events, or irAEs) in 408 patients receiving immune checkpoint inhibitor (ICI) therapy between January 16 and March 27, 2021. They found no increase in type, frequency, or severity of side effects from those receiving both immunotherapy and the vaccine at the same time.

Key Points: 
  • "This was surprising, since there is overwhelming evidence of higher risk for COVID-19-infection related complications in patients actively receiving cancer treatment.
  • More than 25,000 oncologists and other cancer care professionals across the United States readJNCCNJournal of the National Comprehensive Cancer Network.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .
  • Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.

mRNA Cancer Therapies Patent Landscape 2022: Description and Analysis of Key Players, Patents & Trends

Retrieved on: 
Monday, October 17, 2022
RNA transfection, DC, 3, Vaccine, GMP, Cytokine, Neoplasm, CspA mRNA 5′ UTR, RNA, COVID-19, CureVac, Technology, BioNTech, Knowledge, IP, Patent, SaRNA, Protein, Vaccination, Cancer, Antigen

DUBLIN, Oct. 17, 2022 /PRNewswire/ -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 17, 2022 /PRNewswire/ -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering.
  • In cancer immunotherapy, the most advanced application of mRNA is therapeutic vaccination with mRNA encoding antigens, i.e., direct cancer vaccines or dendritic cell vaccines.
  • mRNA cancer therapies have been investigated and the selected patent families are labelled according to the technologies to which they relate.
  • The patent portfolio analysis of key players includes a description of the assignee, key numbers in terms of patents, time evolution of patent publication, main geographical coverage and live patents by technical segment.

eXp World Holdings, Inc. Announces Viome as Precision Nutrition Health Partner in SUCCESS Health

Retrieved on: 
Thursday, October 13, 2022
Gene expression, U.S. Securities and Exchange Commission, RNA transfection, Medicine, Therapy, Exp, Growth, Health, Annual report, 3D, Biology, Sleep, Inflammation, Nasdaq, Cancer, World, Hold On (Children of the Sky), Goal, SUCCESS, Exercise, AI, CEO, Ecosystem, Conditional sentence, Food, GLOBE, United Kingdom, Ageing, Pharmacy, Solution, Biochemistry, Dietary supplement, Pharmaceutical industry

BELLINGHAM, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), the holding company for eXp Realty, Virbela and SUCCESS Enterprises, today announced Viome Life Sciences as its precision nutrition health partner in the newly launched SUCCESS Health, which provides valuable tools and resources to help consumers transform their health and wellness.

Key Points: 
  • BELLINGHAM, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), the holding company for eXp Realty, Virbela and SUCCESS Enterprises, today announced Viome Life Sciences as its precision nutrition health partner in the newly launched SUCCESS Health, which provides valuable tools and resources to help consumers transform their health and wellness.
  • SUCCESS Health is focused on three key health offerings for consumers: specially curated content, individual and group health coaching and a community of health partners.
  • At the foundation of SUCCESS Health are four key pillars of great health: nutrition, exercise, stress reduction and sleep, with Viome the first health partner to focus on nutrition.
  • eXp World Holdings, Inc. (Nasdaq: EXPI) is the holding company for eXp Realty, Virbela and SUCCESS Enterprises.

AGC Biologics Honored for Innovations in Cell Line Development

Retrieved on: 
Thursday, October 13, 2022
AI Global Media, Plasmid, RNA transfection, Immortalised cell line, PD, Specialization, Escherichia coli, Contract, Research, RNA, Degenerative disease, CO, CDMO, Mab, CLD, GLOBE, DNA, AGC, Fine chemical

AGC Biologics has a Cell Line Development program backed by several decades of scientific expertise and research.

Key Points: 
  • AGC Biologics has a Cell Line Development program backed by several decades of scientific expertise and research.
  • Further, AGC Biologics in-house quality and regulatory teams ensure cell line development projects are ready for any stage, across any regulatory market, anywhere in the world.
  • AGC Biologics also invests in the latest research and development needs for its Cell Line Development program, including evaluating CHO-K1 GS knockout cell lines and transposase technology for increased DNA integration and high-producing cell lines, to diversify its portfolio.
  • AGC Biologics currently has four locations offering cell line development services, Seattle, WA and Boulder, CO , USA, Copenhagen, Denmark , and Chiba, Japan .